Physician profile
Jad Sallit
NPI 1316501141
$1,249.76
in general payments reported to CMS, 2019-2025
25 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $318 · 2023: $277 · 2024: $306 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $183.53 | 2023-2025 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $149.23 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.91 | 2022-2024 | Trintellix |
| Novo Nordisk INC | $120.70 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $87.26 | 2022-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $70.62 | 2023-2024 | Mounjaro |
| Abbvie INC. | $68.04 | 2022-2024 | Linzess |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.81 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $37.46 | 2022-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.18 | 2022-2023 | Jardiance |
| Inspire Medical Systems, INC. | $34.38 | 2024 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $30.59 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.73 | 2024 | Voquezna |
| Acella Pharmaceuticals, LLC | $19.73 | 2025 | NP Thyroid 60 |
| Otsuka America Pharmaceutical, INC. | $19.53 | 2023 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $19.13 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $19.13 | 2023 | Shingrix |
| Seqirus USA INC | $19.11 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.18 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $16.85 | 2025 | Neffy |
| Boston Scientific Corporation | $16.55 | 2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $14.64 | 2022 | |
| Astellas Pharma US INC | $14.51 | 2022 | |
| Merck Sharp & Dohme LLC | $14.50 | 2022 | |
| Daiichi Sankyo INC. | $13.46 | 2025 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jad Sallit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.